CRNX
NASDAQCrinetics Pharmaceuticals Inc.
Price$84.96-0.01 (-0.01%)
01:30 PM08:00 PM
News · 26 weeks85+343%
2026-03-082026-08-30
Mix5990d
- SEC Filings23(39%)
- Insider22(37%)
- Other9(15%)
- Earnings3(5%)
- Analyst1(2%)
- Leadership1(2%)
Latest news
25 items- INSIDERDirector Vivaldi Coelho Rogerio returned $1,634,125 worth of shares to the company (19,225 units at $85.00), closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Wierenga Wendell returned $10,376,035 worth of shares to the company (122,071 units at $85.00), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Okey Stephanie returned $1,047,625 worth of shares to the company (12,325 units at $85.00), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Fust Matthew K returned $2,444,685 worth of shares to the company (28,761 units at $85.00), closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Nichols Weston returned $1,889,125 worth of shares to the company (22,225 units at $85.00), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Deardorf Caren returned $1,889,125 worth of shares to the company (22,225 units at $85.00), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERDirector Bedrosian Camille L returned $1,889,125 worth of shares to the company (22,225 units at $85.00), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERChief Commercial Officer Kalofonos Isabel returned $3,031,865 worth of shares to the company (35,669 units at $85.00), closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERChief Scientific Officer Betz Stephen F. returned $11,724,560 worth of shares to the company (137,936 units at $85.00), closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERChief Financial & Infra. Ofcr. Schilke Tobin returned $6,751,295 worth of shares to the company (79,427 units at $85.00), closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERPresident & CEO Struthers Richard Scott returned $119,247,435 worth of shares to the company (1,402,911 units at $85.00), closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form S-8 POS filed by Crinetics Pharmaceuticals Inc.S-8 POS - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form POSASR filed by Crinetics Pharmaceuticals Inc.POSASR - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form POSASR filed by Crinetics Pharmaceuticals Inc.POSASR - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form 25-NSE filed by Crinetics Pharmaceuticals Inc.25-NSE - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- SECCrinetics Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- PRVertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership TeamCrinetics acquisition completed September 1, 2026 Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately As part of a planned transition, Jonathan Poole, current SVP Finance, will be appointed EVP, CFO, effective January 1, 2027, and Mr. Wagner will continue as EVP, COO Jasper van Grunsven to join Vertex as EVP, Chief Pain and New Product Planning Officer in September Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, developme
CRNX FAQ
7 questionsWhat does Crinetics Pharmaceuticals Inc. do?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide...Where does CRNX stock trade?
Crinetics Pharmaceuticals Inc. (CRNX) is listed on NASDAQ.What sector and industry is CRNX in?
Crinetics Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Crinetics Pharmaceuticals Inc. go public?
Crinetics Pharmaceuticals Inc. (CRNX) completed its IPO in 2018.What are analysts saying about CRNX?
Crinetics Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-07-02. Recent price targets cluster around $3600.00.What companies are similar to CRNX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CRNX side-by-side with any of them on Quantisnow.How can I track CRNX on Quantisnow?
Quantisnow aggregates Crinetics Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRNX to receive live email and push alerts on every new disclosure.